These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36727462)

  • 21. Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer.
    Erdmann É; Ould Madi Berthélémy P; Cottard F; Angel CZ; Schreyer E; Ye T; Morlet B; Negroni L; Kieffer B; Céraline J
    Mol Oncol; 2022 Jul; 16(13):2518-2536. PubMed ID: 34919781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
    Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
    Beketova E; Fang S; Owens JL; Liu S; Chen X; Zhang Q; Asberry AM; Deng X; Malola J; Huang J; Li C; Pili R; Elzey BD; Ratliff TL; Wan J; Hu CD
    Cancer Res; 2020 Nov; 80(22):4904-4917. PubMed ID: 32999000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4.
    Kang HY; Huang KE; Chang SY; Ma WL; Lin WJ; Chang C
    J Biol Chem; 2002 Nov; 277(46):43749-56. PubMed ID: 12226080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
    Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
    Urbanucci A; Sahu B; Seppälä J; Larjo A; Latonen LM; Waltering KK; Tammela TL; Vessella RL; Lähdesmäki H; Jänne OA; Visakorpi T
    Oncogene; 2012 Apr; 31(17):2153-63. PubMed ID: 21909140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
    Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
    Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 39. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
    Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
    Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.